ABIONYX Pharma SA (FRA:609)

Market Cap	131.06M +204.8%
Revenue (ttm)	4.10M -9.9%
Net Income	-5.50M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	334
Open	3.270
Previous Close	3.030
Day's Range	3.270 - 3.270
52-Week Range	1.096 - 5.000
Beta	n/a
RSI	50.31
Earnings Date	Mar 12, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 51
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 609

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.10 million, a decrease of -9.91% compared to the previous year's 4.55 million. Losses were -5.50 million, 25.5% more than in 2024.